Since these two types of genetic alterations, i.e., SPOP mutations and TMPRSS2-ERG fusions, similarly lead to ERG stabilization, it is conceivable that their incidences are mutually exclusive in prostate cancers (93). This evidence concerns the gene ERG and prostate carcinoma.